AnaptysBio, Inc. Securities Fraud Class Action

AnaptysBio, Inc. Securities Fraud Class Action

CompanyAnaptysBio, Inc.
CourtUnited States District Court for the Southern District of California
Case Number20-cv-00565
JudgeHonorable Todd W. Robinson
Class PeriodOctober 10, 2017 through November 7, 2019
Security TypeCommon Stock

Case Background: 
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired AnaptysBio, Inc. (“AnaptysBio”) (NASDAQ: ANAB) common stock between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made false and misleading statements regarding the purported efficacy of etokimab, AnaptysBio’s targeted treatment for inflammatory diseases, touting data from the company’s Phase 2a trial in peanut allergies as showing a “remarkable efficacy result” and describing the drug as having a “pretty profound efficacy” in its treatment of patients with atopic dermatitis. Specifically, the complaint alleges that Defendants provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab’s efficacy and its prospects appear far better than they were.

Current Status of Case:
On November 30, 2021, the Court granted Defendants’ Motion to Dismiss. This action has concluded.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. 

Complete this form with your transactions in AnaptysBio, Inc. between October 10, 2017 through November 7, 2019.

    Submit Your Information
    SUBMIT YOUR INFORMATION
    * Denotes required field
    Phone Country code
    Purchase Information
    Sales Information
    Did you purchase shares of AnaptysBio, Inc. prior to the Class Period?
    Are you a current or former employee of AnaptysBio, Inc.?
    The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. READ MORE
    I agree to the KTMC disclaimer
    I would like to receive new case alerts by email
    Scroll to Top